An unexpected catalyst is reshaping fitness equipment categories this year: weight-loss drugs.
According to The 2025 China Large-Scale Fitness Equipment White Paper(Huaxinren Consulting, co-researched with UBS), the rapid adoption of GLP-1 medications (Ozempic, Wegovy, Mounjaro) is creating a side-effect problem—muscle loss. That, in turn, is driving a surge in demand for strength-training equipment as users scramble to preserve lean mass while shedding fat.
The numbers tell the story. While cardio remains steady, strength equipment is the faster-growing category in both home and commercial segments in 2025. A dark-horse sub-category: climbing trainers (fitness stair-steppers), which offer high calorie burn in a small footprint and are outgrowing traditional treadmills and ellipticals in several regional markets.
Commercial gyms are reconfiguring floor plans. "We're seeing chains allocate 40–50% of new floor space to strength zones, up from 25–30% pre-GLP-1," noted one equipment distributor at IHRSA 2025. Home buyers, too—adjustable dumbbells, stack-loaded home power racks, and smart cable machines are trending upward in North America and APAC e-commerce channels.
The synergy makes sense: GLP-1 users typically work with dietitians who prescribe resistance training 2–3x/week to counteract sarcopenia risk. Equipment makers are responding with lighter-start resistance curves, AI-form coaching (critical when users are novices), and connected apps that sync with health platforms to track muscle-mass retention.
For an industry that spent a decade pivoting around "cardio-at-home" (Peloton, Zwift, rowing), the GLP-1 tailwind is a reminder that pharma and fitness hardware are now odd bedfellows—but profitable ones.
